Program-Wednesday, April 04, 2007 -3th day

Wednesday, April 04, 2007

INVITED LECTURE – 6 (Co-Chairs: Lowrie Powell, Hisao Hayashi)

08:30 am – 09:00 am

IL-11: The Pathogenesis of Porphyria Cutanea Tarda

James Kushner, MD

09:00 am – 09:30 am

IL-12: Fibrosis

Grant A. Ramm, BSc, PhD

INVITED LECTURE -7 (Co-Chairs: Robert Fleming, Pensri Pootrakul)

09:30 am – 10:00 am

IL-13: Secondary Iron Overload and ICL670

Antonio Piga, M.D.

10:00 am – 10:30 am

IIL-14: QUANTITATIVE IMAGING OF HUMAN LIVER IRON CONCENTRATIONS IN VIVO

T. St. Pierre, PhD, A. Fleming, BSc, W. Chua-anusorn, PhD, P. Clark, PhD, E. Rossi, PhD, G. Jeffrey, MD/PhD and J. Olynyk, MD/PhD, The University of Western Australia (Presented By: T. St. Pierre, PhD)

10:30 am – 11:00 am

Break

01:30 pm – 04:10 pm

NOVARTIS SYMPOSIUM: IRON LOADING AND ITS CLINICAL IMPLICATIONS (Co-Chairs: Antonello Pietrangelo, Chaim Hershko)

PLENARY SESSION – 1 (Co-Chairs: Paulo Arosio, Fumio Kishi)

11:00 am – 11:20 am

PL-01: GROWTH DIFFERENTIATION FACTOR 15 IS PRODUCED AT HIGH LEVELS IN PATIENTS WITH BETA THALASSEMIA AND INHIBITS HEPCIDIN EXPRESSION IN PRIMARY

T. Tanno, DVM, PhD, N. Bhanu, PhD, P. Oneal, MD, S. Goh, PhD, P. Staker, T. Lee, R. Childs, MD, S. Leitman, MD, N. Luban, MD and J. Miller, MD, Molecular Medicine Branch/ NIDDK/ NIH (Presented By: T. Tanno, DVM, PhD)

11:20 am – 11:40 am

PL-02: AN ADVANCED IRON-METABOLISM MICROCHIP FOR LARGE SCALE POPULATION SCREENING OF MUTATIONS AND POLYMORPHISMS IN GENES INVOLVED IN IRON METABOLISM

L. Cremonesi, PhD, S. Bonalumi, F. Ferrari, A. Brisci, N. Soriani, B. Foglieni, C. Camaschella, M.Cazzola, G. Biasiotto, P. Arosio and M. Ferrari, Genomic Unit for the Diagnosis of Human Pathologies, (Presented By: L. Cremonesi, PhD)

11:40 am – 12:00 pm

PL-03: METAL DISTRIBUTION AND GENE EXPRESSION PROFILE IN DMT1 KNOCKOUT MICE

H. Gunshin, PhD, C. Tohyama, PhD, Y. Vainshtein, PhD, M. Hentze, MD, M. Muckenthaler, PhD and N. Andrews, MD, PhD, University of Massachusetts (Presented By: H. Gunshin, PhD)

11:00 am – 12:00 pm

Concurrent Session 5: No, Oxygen, HO, Oxydative Stress (Co-Chairs: Roberta Ward, Yuzou Nishida)

Location: Hall II (Room C-1)

11:00 am

O-21: NITRIC OXIDE (NO+) ENHANCES FERRITIN SYNTHESIS BY BOTH IRP-DEPENDENT AND -INDEPENDENT MECHANISMS

M. Mikhael, BSc, S. Kim, BSc, MSc, PhD, M. Schranzhofer, BSc, MSc, PhD, S. Soe-Lin, BSc, A. Sheftel, BSc, PhD, E. Mullner, BSc, MSc, PhD and P. Ponka, BSc, MD, PhD, Lady Davis Institute, Rm 202 (Presented By: M. Mikhael, BSc)

11:15 am

O-22: CROSSTALK BETWEEN OXYGEN AND IRON METABOLISM: IRON-REGULATORY PROTEINS LIMIT HYPOXIA INDUCIBLE FACTOR 2 ALPHA EXPRESSION IN IRON DEFICIENCY

M. Sanchez, PhD, B. Galy, PhD, M. Muckenthaler, Prof, PhD and M. Hentze, Prof, PhD, European Molecular Biology Laboratory (EMBL) (Presented By: M. Sanchez, PhD)

11:30 am

O-23: THE IRON STORAGE FUNCTION OF FERRITIN H PROTECTS CELLS FROM IRON TOXICITY BY OXIDATIVE DAMAGE

L.C. Khn, L. Richman, D. Darshan, Swiss Institute for Experimental Cancer Research (ISREC), Epalinges, Switzerland

11:45 am

O-24: TRANSGENIC OVEREXPRESSION OF HEME OXYGENASE-1 INDUCES IRON AND PORPHYRIN ACCUMULATION IN MICE

L. Zhou, MsSci, X. Gao, PhD, Y. Togashi, BachelorSci, M. Satoh, PhD, M. Yamamota, PhD, T. Yoshida, PhD and O. Nakajima, PhD, Research Laboratory for Molecular Genetics, Yamagata University (Presented By: L. Zhou, MsSci)

11:00 am – 12:00 pm

Concurrent Session 6: Cancer (Co-Chairs: Des Richardson, Junji Kato)

Location: Hall III (Room C-2)

11:00 am

O-35: REDUCTION OF HEPATIC 8-OH-DG LEVELS AND HISTOLOGICAL IMPROVEMENT IN NON-ALCOHOLIC STEATOHEPATITIS PATIENTS UNDERGOING IRON DEPLETION THERAPY BY PHLEBOTOMY AND LOW IRON DIET

K. Takada, J. Kato, Y. Kawano, M. Kobune, R. Takimoto, S. Takahashi, K. Takanashi, K. Miyanishi and Y. Niitsu, Sapporo Med Univ Sch Med, 4th Dept Int Med (Presented By: K. Takada)

11:15 am

O-36: HEPATIC IRON OVERLOAD IN A WILSON DISEASE MODEL OF LONG-EVANS CINNAMON RATS

H. Hayashi, MD, M. Yano, MD, S. Wakusawa, PhD, Y. Fujita, BS, K. Hayashi, MD, Y. Katano, MD and H. Goto, MD, Aichi Gakuin University School of Pharmacy (Presented By: H. Hayashi, MD)

11:30 am

O-37: A MODULATION OF IRON TRANSPORT PROTEINS IN OESOPHAGEAL ADENOCARCINOMA

C. Tselepis, Bsc PhD, M. Brookes, MBChB, MRCP, J. Boult, BMedSci, K. Roberts, MBChB, G. Anderson, PhD, R. Spychal, MD, FRCS and T. Iqbal, MD, FRCP, University of Birmingham (Presented By: C. Tselepis, Bsc PhD)

11:45 am

O-38: EXPRESSION OF HCP-1 IN OESOPHAGEAL CARCINOGENESIS

T. Iqbal, M. Brookes, MBChB, K. Roberts, MBChB, J. Boult, BMedSci, A. McKie, PhD, R. Spychal, MD and C. Tselepis, PhD, CRUK Institute for Cancer Studies (Presented By: T. Iqbal)

12:00 pm – 01:30 pm

Lunch

01:30 pm – 04:00 pm

Presidential Symposium: New Approaches to Therapy for Iron-Related Disease(Co-Chairs: Jerry Kaplan, Piere Brissot)

01:30 pm – 01:45 pm

Introduction

Pierre Brissot

01:45 pm – 02:00 pm

PS-01: SALMONELLA TYPHIMURIUM INFECTION AND IRON METABOLISM IN MICE PRESENTING CONSTITUTIVE HEMOLYTIC ANEMIA

Y. Ma, MD, PhD, Y. Okazaki, MD, PhD, M. Yeh, MS, K. Yeh, PhD and J. Glass, MD, Feist-Weiller Cancer Center, LSUHSC (Presented By: Y. Okazaki, MD, PhD)

03:30 pm

O-09: SUSTAINED HYDROGEN PEROXIDE INDUCES IRON UPTAKE BY TRANSFERRIN RECEPTOR-1 INDEPENDENT OF THE IRP/IRE NETWORK

F. Canonne-Hergaux, PhD, M. Roy, PhD, O. Thibaudeau, Technician, N. Riendeau, C. Bdard, P. Hlie and D. Malo, PhD, INSERM-CNRS (Presented By: F. Canonne-Hergaux, PhD)

02:00 pm – 02:15 pm

PS-02: SELECTIVE REDUCTION OF CEREBELLAR IRON ACCUMULATION IN FRIEDREICH’S ATAXIA ATTAINED BY A MODERATE DEFRIPRONE CHELATION TREATMENT

A. Munnich, MD PhD, N. Boddaert, MD, A. Roetig, PhD and I. Cabantchik, MD PhD, Hebrew University of Jerusalem (Presented By: I. Cabantchik, MD PhD)

02:15 pm – 02:30 pm

PS-03: ONCE-DAILY, ORAL CHELATION WITH DEFERASIROX (EXJADE, ICL670) ROVIDES SUSTAINED PROTECTION FROM LABILE PLASMA IRON IN B-THALASSEMIA PATIENTS

S. Daar, A. Taher, A. Pathare, H. Nick, U. Krahn and D. Hadler, Novartis Pharmaceuticals (Presented By: H. Nick)

02:30 pm – 02:45 pm

PS-04: PK/PD PROFILES DURING DEFERASIROX (EXJADE, ICL670) TREATMENT ARE SIMILAR IN JAPANESE AND CAUCASIAN PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD

S. Iki, A. Urabe, T. Hata, K. Ohyashiki, S. Nakao, M. Takatoku, T. Ishikawa, J. Kato, Y. Tatsumi,H. Mori, H. Tanii, J. Taniguchi, M. Kondo, H. Schran and B. Rabault, NTT Kanto Medical Center (Presented By: A. Urabe)

02:45 pm – 03:00 pm

PS-05: IN VITRO PROTECTION BY SALICYLALDEHYDE ISONICOTINOYL HYDRAZONE (SIH) AGAINST ANTHRACYCLINE-INDUCED TOXICITY TO CARDIAC CELLS

T. Simunek, PhD, H. Kaiserova, MSc, M. Sterba, MSc, O. Popelova, MSc, M. Adamcova, PhD, P. Ponka, PhD and V. Gersl, PhD, Charles University in Prague, Faculty of Pharmacy, Department of Biochemical Sciences (Presented By: T. Simunek, PhD)

03:00 pm – 03:15 pm

PS-06: ENHANCED IRON UTILIZATION AND CORRECTION OF INFLAMMATION INDUCED ANEMIA BY ORALLY ACTIVE HIF PROLYL HYDROXYLASE INHIBITORS

I. Langsetmo, DVM; PhD, S. Todd, PhD, S. Oksana, PhD, S. Robert, PhD, G. David, MS, A. Michael, PhD, F. Lee A, PhD, L. Al, MD; PhD, L. David, PhD and S. Klaus, PhD, FibroGen, Inc. (Presented By: S. Klaus, PhD)

03:15 pm – 03:30 pm

PS-07: CURCUMIN, A CANCER CHEMOPREVENTIVE AGENT, IS A BIOLOGICALLY RELEVANT IRON CHELATOR

S. Torti, PhD, Y. Jiao, PhD, D. Kennedy, J. Cho, R. Planalp, PhD, F. Bou-Abdallah, PhD, N. Chasteen, PhD, J. Wilkinson IV, PhD, W. Wang and F. Torti, MD, Wake Forest University Health Sciences (Presented By: S. Torti, PhD)

03:30 pm – 03:45 pm

PS-08: GENE REGULATION THERAPY FOR SICKLE CELL DISEASE UTILIZING FERRITIN HEAVY CHAIN

R. Broyles, PhD, V. Belegu, PhD, A. Roth, BS, E. Clarkson, BS, K. Williamson, MS, C. Stewart, PhD, Q. Pye, MS, R. Floyd, PhD, K. Jani, PhD, M. Trudel, DSc, P. Santambrogio, PhD, S. Levi, PhD, P. Arosio, PhD and J. Cain, MD, University of Oklahoma Health Sciences Center (Presented By: R. Broyles, PhD)

03:45 pm – 04:00 pm

Closing Remarks

Jerry Kaplan, PhD

04:00 pm – 05:00 pm

EVENING SEMINAR: (Chair: Robert Crichton) co-sponsored by Chugai Pharmaceutical Co., Ltd.,

04:00 pm – 04:30 pm

ES-01: FRIEDREICH´S ATAXIA:CLINICAL PILOT TRIAL WITH RECOMBINANT HUMAN ERYTHROPOIETIN

B. Scheiber-Mojdehkar, PhD, S. Boesch, MD, S. Hering, MD, H. Goldenberg, Prof PhD, W. Poewe, MD and B. Sturm, PhD, Medical University of Vienna, Department of Medical Chemistry (Presented By: B. Scheiber-Mojdehkar, PhD)

01:30 pm – 02:45 pm

Concurrent Session 7: Erythropoiesis (Co-Chairs: Stefano Rivella, Osamu Nakajima)

Location: Hall II (Room C-1)

01:30 pm

O-25: IRON IS DIRECTLY TRANSFERRED FROM ENDOSOMES TO MITOCHONDRIA IN HEMOGLOBIN-SYNTHESIZING CELLS

A. Sheftel, PhD, T. Kahawita, BSc, A. Zhang, MD, C. Brown, PhD, O. Shirihai, MD, PhD and P. Ponka, MD, PhD, Lady Davis Instute, McGill University (Presented By: A. Sheftel, PhD)

01:45 pm

O-27: TRANSGENIC RESCUE OF ERYTHROID 5-AMINOLEVULINATE SYNTHASE-DEFICIENT MICE RESULTS IN THE FORMATION OF RING SIDEROBLASTS AND SIDEROCYTES

M. Schranzhofer, PhD, M. Schifrer, MS, P. Ponka, MD, PhD and E. Mullner, PhD, Lady Davis Institute for Medical Research, McGill University (Presented By: M. Schranzhofer, PhD)

02:00 pm

O-27: TRANSGENIC RESCUE OF ERYTHROID 5-AMINOLEVULINATE SYNTHASE-DEFICIENT MICE RESULTS IN THE FORMATION OF RING SIDEROBLASTS AND SIDEROCYTES

O. Nakajima, PhD, S. Okano, PhD, H. Harada, PhD,MD, T. Kusaka, PhD, X. Gao, PhD, T. Hosoya, PhD, N. Suzuki, PhD, S. Takahashi, PhD,MD and M. Yamamoto, PhD,MD, Research Laboratory for Molecular Genetics, Yamagata University (Presented By: O. Nakajima, PhD)

02:15 pm

O-28: ORGAN IRON DISTRIBUTION IN BETA-THALASSEMIA IS MEDIATED BY THE LEVEL OF ERYTHROPOIESIS AND IRON ABSORPTION RATHER THAT RED CELL APOPTOSIS OR HEMOLYSIS

S. Rivella, PhD, I. Libani, R. Schiro’, MD, T. Scholzen, PhD, P. Ramos, E. Guy, M. Kernbach, PhD, B. Baron-Luehr, PhD, L. Breda, PhD, M. Cappellini, MD, R. Grady, PhD, J. Gerdes, PhD and P. Giardina, MD, Weill Medical College of Cornell University (Presented By: S. Rivella, PhD)

2:30 pm

O-29: A PROTEOMIC ANALYSIS ON ERYTHROID ACTIVE PROTEIN EXPRESSION DURING DIFFERENTIATION OF FRIEND MURINE ERYTHROLEUKEMIA CELLS

C. Lok, PhD, Q. He, PhD and J. Chiu, PhD, The University of Hong Kong (Presented By: C. Lok, PhD)

01:30 pm – 02:45 pm

Concurrent Session 8: Hepcidin (Co-Chairs: Elizabeth Nemeth, Naohisa Tomosugi)

Location: Hall III (Room C-2)

01:30 pm

O-39: EVIDENCE THAT INHIBITION OF HEMOJUVELIN SHEDDING IN RESPONSE TO IRON IS MEDIATED THROUGH NEOGENIN

A. Zhang, S. Anderson, K. Meyers, C. Hernandez, R. Eisenstein and C. Enns, Oregon Health & Science University (Presented By: A. Zhang)

01:45 pm

O-40: THE ERYTHROPOIETIC REGULATOR OF HEPCIDIN CIRCULATES IN PLASMA

S. Rivera, MD, PhD, M. Pak, MD, Y. Desyatnikov, V. Gabayan and T. Ganz, PhD, MD, University of California, Los Angeles (Presented By: S. Rivera, MD, PhD)

02:00 pm

O-41: MOLECULAR MECHANISM OF HEPCIDIN-INDUCED DEGRADATION OF FERROPORTIN

D. Ward, PhD, I. De Domenico, PhD, C. Langelier, BS, M. Vaughn, BS, E. Nemeth, PhD, W. Sundquist, PhD, T. Ganz, MD, G. Musci, BS and J. Kaplan, PhD, University of Utah (Presented By: D. Ward, PhD)

02:15 pm

O-42: HEPCIDIN GENE EXPRESSION IS FURTHER SUPPRESSED IN HFE-/- MICE FOLLOWING CHRONIC ETHANOL CONSUMPTION.

L. Fletcher, PhD, M. Heritage, PhD, K. Bridle, PhD, T. Murphy, MSc, G. Anderson, PhD and D. Crawford, MD, FRACP, Dept Gastroenterology and Hepatology, Princess Alexandra Hospital (Presented By: L. Fletcher, PhD)

02:30 pm

O-43: ANTI-INTERLEUKIN 6 RECEPTOR ANTIBODY TOCILIZUMAB REDUCES THE LEVELS OF SERUM HEPCIDIN IN PATIENTS WITH MULTICENTRIC CASTLEMAN’S DISEASE

H. Kawabata, MD, N. Tomosugi, MD, J. Kanda, MD, Y. Tanaka, MD, N. Kadowaki, MD, T. Ichinohe, MD, T. Ishikawa, MD and T. Uchiyama, MD, Department of Hematology and Oncology,Graduate School of Medicine, Kyoto University (Presented By: H. Kawabata, MD)

02:45 pm – 04:00 pm

Concurrent Session 9: Brain Iron Degeneration (CNS) (Chairs: Marco T. Nunez, Kazuhisa Taketa)

Location: Hall II (Room C-1)

02:45 pm

O-30: REGIONAL AND CELLULAR DISTRIBUTION OF MITOCHONDRIAL FERRITIN IN THE MOUSE BRAIN

J. Connor, PhD, A. (Snyder) Ill, G. Baisiotto, P. Arosio and S. Levi, Pennsylvania State University College of Medicine (Presented By: J. Connor, PhD)

03:00 pm

O-31: DOWN REGULATION OF FERROPORTIN IN ALZHEIMER’S AND PARKINSON’S DISEASE AND THE AGEING BRAIN: IMPLICATIONS FOR AXONAL IRON TRANSPORT AND DEGRADATION BY AUTOPHAGY OR PROTEOSOMAL PATHWAYS

J. Kwok, PhD, J. Zhao, PhD, L. Rodrick, PhD, A. Bomford, MBBS, FRCP and R. Raha-Chowdhury, PhD, UNIVERSITY OF CAMBRIDGE (Presented By: R. Raha-Chowdhury, PhD)

03:15 pm

O-32: UP-REGULATION OF LON PROTEASE IS ASSOCIATED WITH THE DECREASE IN MITOCHONDRIAL FE-S PROTEIN LEVELS IN A MOUSE MODEL OF FRIEDREICH ATAXIA

C. Bouton, PhD, B. Guillon, Engineer, A. Bulteau, PhD, H. Puccio, PhD and J. Drapier, PhD, Institut de Chimie des Substances Naturelles-CNRS (Presented By: C. Bouton, PhD)

03:30 pm

O-33: THE FUNCTIONAL POLYMORPHISM OF THE HEMOGLOBIN-BINDING PROTEIN HAPTOGLOBIN INFLUENCES SUSCEPTIBILITY TO IDIOPATHIC PARKINSON’S DISEASE

S. Sadrzadeh, PhD, P. Costa-Mallen, PhD, A. Zabeti, MD, M. Edenfield, BS, P. Swanson, MD, W.Longstreth, MD, G. Franklin, MD, T. Smith-Weller, COHN and H. Checkoway, PhD, University of Washington (Presented By: S. Sadrzadeh, PhD)

03:45 pm

O-34: HEPATIC IRON OVERLOAD ASSOCIATED WITH A DECREASED SERUM CERULOPLASMIN LEVEL IN A NOVEL CLINICAL TYPE OF A ACERULOPLASMINEMIA

S. Kono, MD, H. Miyajima, MD, H. Suzuki, MD, K. Takahashi, MD, Y. Takahashi, MD, K. Shirakawa, MD, Y. Murakawa, MD and S. Yamaguchi, MD, First Department of Medicine, Hamamatsu University School of Medicine (Presented By: S. Kono, MD)

02:45 pm – 04:00 pm

Concurrent Session 10: Regulatory System of Iron Metabolism (Co-Chairs: Hiromi Gunshin, Takeshi Nakanishi)

Location: Hall III (Room C-2)

02:45 pm

O-44: WILD-TYPE FERROPORTIN IS NOT IMPEDED IN MATURATION, CELL SURFACE EXPRESSION OR IRON EXPORT FUNCTION BY MUTANT FERROPORTIN, AND BIO-LUMINESCENCE RESONANCE ENERGY TRANSFER (BRET) EXPERIMENTS INDICATE MONOMERIC FORM IN CELL MEMBRANES

L. Schimanksi, BSc, MSc, H. Drakemth, BA, PhD, C. Talbot, BA, K. Horne, BA, J. James, BSc, E. Sweetland, BSc, MSc, J. Bastin, BSc, PhD, D. Cowley, D. Simon, PhD and A. Townsend, PhD, MBBS, Oxford University (Presented by: L. Schimanski, BSc, MSc)

03:00 pm

O-45: THE FLATIRON MUTATION IN MOUSE FERROPORTIN ACTS AS A DOMINANT NEGATIVE TO CAUSE HEMOCHROMATOSIS TYPE IV

I. De Domenico, PhD, I. Zohn, PhD, A. Pollack, BS, D. Ward, PhD, J. Goodman, BS, X. Liang, BS, A. Sanchez, BS, L. Niswander, PhD and J. Kaplan, PhD, University of Utah (Presented By: I. De Domenico, PhD)

03:15 pm

O-46: IDENTIFICATION OF NEW LIGANDS FOR THE HAEMOCHROMATOSIS PROTEIN HFE

H. Drakesmith, BA, PhD, E. Sweetland, MSc, D. Li, PhD, L. Schimanski, MSc, J. Bastin, PhD, D. Cowley, X. Xu, PhD and A. Townsend, PhD, MBBsc, Molecular Immunology Group, WeatherallInstitute of Molecular Medicine (Presented By: H. Drakesmith, BA, PhD)

03:30 pm

O-47: DISEASE CAUSING MUTATIONS OF TRANSFERRIN RECEPTOR 2 CAUSE ITS INTRACELLULAR RETENTION

V. Subramaniam, M Sc, PhD, L. Summerville, BSc, GradDip and D. Wallace, BSc (Hons), PhD, Queensland Institute of Medical Research (Presented By: V. Subramaniam, M Sc, PhD)

03:45 pm

O-48: THE BINDING OF TRANSFERRIN RECEPTOR 2 TO THE HEREDITARY HEMOCHROMATOSIS PROTEIN, HFE, ALTERS ITS TRAFFICKING AND STABILITY

C. Enns, PhD, M. Chloupkova, J. Chen and J. Gao, Oregon Health & Science University (Presented By: C. Enns, PhD)